Participating Faculty for the Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

December 9, 2020
Supplements and Featured Publications, The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective,

FACULTY

Michael Heile, MD, FAAFP

TriHealth Physician Partners

Cincinnati, OH

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

Senior Director

Clinical Analytics

WellDyne

Lakeland, FL

Tanya Dougherty, PharmD, BCPS

Population Health Pharmacist

Jefferson Health

Philadelphia, PA

Helena W. Rodbard, MD, FACP, MACE

Medical Director

Endocrine and Metabolic Consultants

Rockville, MD

Ildiko Lingvay, MD, MPH, MSCS

Professor of Medicine

Department of Internal Medicine/Endocrinology

Department of Population and Data Sciences

University of Texas Southwestern Medical Center

Dallas, TX

Doron Schneider, MD

Vice President

Population Health Services

Tandigm Health

Conshohocken, PA

FACULTY DISCLOSURES

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Michael Heile, MD, FAAFP

SPEAKER

Novo Nordisk Inc

STOCK OWNERSHIP

Novo Nordisk Inc

Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP

ADVISORY BOARD

Novo Nordisk

Helena W. Rodbard, MD, FACP, MACE

CONSULTANT

AstraZeneca; Boehringer Ingelheim; Janssen; Lexicon; Lilly; Merck; Novo Nordisk Inc; Sanofi

GRANT SUPPORT

AstraZeneca; Boehringer Ingelhein; Janssen; Lexicon; Lilly; Novo Nordisk Inc; Sanofi

ADVISORY BOARD

Merck

Ildiko Lingvay, MD, MPH, MSCS

GRANT SUPPORT

GI Dynamics; Merck; Mylan; Novartis; Novo Nordisk Inc; Pfizer

CONSULTANT

AstraZeneca; Boehringer Ingelheim; Duke CRI; Eli Lilly; Intarcia; Intercept; Janssen; Mannkind; Novo Nordisk Inc; Sanofi; TARGETPharma; Valeritas; Zealand

Doron Schneider, MD

SPEAKER

Novo Nordisk Inc

CONSULTANT

Eli Lilly; HealthCast

Tanya Dougherty, PharmD, BCPS

reports no relevant financial relationships with commercial interests.